Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Equity Average (2016 - 2025)

Historic Equity Average for Cardiff Oncology (CRDF) over the last 14 years, with Q3 2025 value amounting to $53.7 million.

  • Cardiff Oncology's Equity Average rose 551.78% to $53.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.7 million, marking a year-over-year increase of 551.78%. This contributed to the annual value of $76.3 million for FY2024, which is 1328.59% down from last year.
  • Latest data reveals that Cardiff Oncology reported Equity Average of $53.7 million as of Q3 2025, which was up 551.78% from $64.7 million recorded in Q2 2025.
  • Cardiff Oncology's Equity Average's 5-year high stood at $137.0 million during Q4 2021, with a 5-year trough of $50.9 million in Q3 2024.
  • Over the past 5 years, Cardiff Oncology's median Equity Average value was $91.5 million (recorded in 2023), while the average stood at $94.8 million.
  • Its Equity Average has fluctuated over the past 5 years, first soared by 178018.93% in 2021, then tumbled by 3812.5% in 2024.
  • Over the past 5 years, Cardiff Oncology's Equity Average (Quarter) stood at $137.0 million in 2021, then decreased by 19.86% to $109.8 million in 2022, then plummeted by 32.79% to $73.8 million in 2023, then fell by 10.32% to $66.2 million in 2024, then decreased by 18.85% to $53.7 million in 2025.
  • Its last three reported values are $53.7 million in Q3 2025, $64.7 million for Q2 2025, and $76.9 million during Q1 2025.